File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: High intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma

TitleHigh intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03 How to Cite?
Abstract
BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and innovative loco-regional treatment for hepatocellular carcinoma (HCC) in recent years. It is an extracorporeal conformal therapy. By targeting a high intensity ultrasound beam at a focal point within the tumor, hyperthermia is induced leading to coagulation necrosis of the tumor cells. We herein report our experience in its clinical application for treatment of recurrent HCC. METHODS: From October 2006 to October 2009, 27 patients received HIFU therapy for recurrent HCC in our center. Their postoperative and survival outcomes were compared with 76 patients who received radiofrequency ablation (RFA) within the same period. P value < 0.05 was considered to be significant. RESULTS: The median age of patients receiving HIFU and RFA was 63 and 62 years old respectively. There was no difference in the frequency of co-morbid illness and hepatitis B positivity between the two groups. The median tumor size in HIFU and RFA group was 1.8 and 1.7 cm respectively (P = 0.28). Operative morbidity rate in the HIFU and RFA group was 7.4 and 22.4% respectively (P = 0.06). Skin burn and liver abscess were the two complications associated with HIFU therapy. There was no hospital mortality in the HIFU group while two deaths were observed in the RFA group. The 1-, 2- and 3-year tumor-free survival rates for HIFU group were 33.3, 22.2 and 0%, respectively, and for RFA group were 26.9, 0, 0%, respectively (P = 0.22). The 1-, 2- and 3-year overall survival rates for HIFU group were 100, 100 and 85.7%, respectively, and for RFA group were 89.1, 71.9 and 62.7%, respectively (P = 0.19). CONCLUSION: Our preliminary experience in utilizing HIFU therapy for treatment of recurrent HCC is promising. Further studies are needed to define its role as a primary treatment of HCC.
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
Persistent Identifierhttp://hdl.handle.net/10722/136095
ISSN
2013 Impact Factor: 2.468
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Aen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorPoon, Ren_US
dc.contributor.authorLo, CMen_US
dc.date.accessioned2011-07-27T02:02:44Z-
dc.date.available2011-07-27T02:02:44Z-
dc.date.issued2011en_US
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03en_US
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/136095-
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011-
dc.description.abstractBACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and innovative loco-regional treatment for hepatocellular carcinoma (HCC) in recent years. It is an extracorporeal conformal therapy. By targeting a high intensity ultrasound beam at a focal point within the tumor, hyperthermia is induced leading to coagulation necrosis of the tumor cells. We herein report our experience in its clinical application for treatment of recurrent HCC. METHODS: From October 2006 to October 2009, 27 patients received HIFU therapy for recurrent HCC in our center. Their postoperative and survival outcomes were compared with 76 patients who received radiofrequency ablation (RFA) within the same period. P value < 0.05 was considered to be significant. RESULTS: The median age of patients receiving HIFU and RFA was 63 and 62 years old respectively. There was no difference in the frequency of co-morbid illness and hepatitis B positivity between the two groups. The median tumor size in HIFU and RFA group was 1.8 and 1.7 cm respectively (P = 0.28). Operative morbidity rate in the HIFU and RFA group was 7.4 and 22.4% respectively (P = 0.06). Skin burn and liver abscess were the two complications associated with HIFU therapy. There was no hospital mortality in the HIFU group while two deaths were observed in the RFA group. The 1-, 2- and 3-year tumor-free survival rates for HIFU group were 33.3, 22.2 and 0%, respectively, and for RFA group were 26.9, 0, 0%, respectively (P = 0.22). The 1-, 2- and 3-year overall survival rates for HIFU group were 100, 100 and 85.7%, respectively, and for RFA group were 89.1, 71.9 and 62.7%, respectively (P = 0.19). CONCLUSION: Our preliminary experience in utilizing HIFU therapy for treatment of recurrent HCC is promising. Further studies are needed to define its role as a primary treatment of HCC.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology Internationalen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleHigh intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, A: acchan@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailPoon, R: poontp@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.authorityChan, A=rp00310en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityPoon, R=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.doi10.1007/s12072-010-9241-z-
dc.identifier.hkuros188339en_US
dc.identifier.volume5en_US
dc.identifier.issue1-
dc.identifier.spage451en_US
dc.identifier.epage451en_US
dc.identifier.isiWOS:000300105300001-
dc.publisher.placeUnited States-
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats